ReviewMovement disorders clinical practice2026
Tracking Genetic Parkinson's Disease with Molecular Imaging: A Systematic Review.
Review in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dopaminergic Radiopharmaceutical Imaging in Parkinsonian Syndromes: From Molecular Targets to Clinical Decision-Making.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundParkinson's disease (PD) is a worldwide, complex neurodegenerative disorder influenced by both genetic and environmental factors. Around 15-20% of PD cases are linked to genetic mutations, providing insights into the disease's pathogenesis.
objectiveThe current review aims to summarize molecular neuroimaging findings in genetic forms of PD, also considering the pre-symptomatic phase of the disease to identify markers distinguishing genetic PD from sporadic forms of the disease as well as early markers of disease conversion.
methodsA literature search on PubMed and Scopus was performed to identify molecular imaging studies on symptomatic and asymptomatic carriers of the following PD-related mutations: SNCA, PRKN, PINK1, PARK7, LRRK2 and GBA1.
resultsA total of 96 studies were summarized to highlight mutation-specific brain alterations, considering dopaminergic and extra-dopaminergic systems (serotonin, acetylcholine), metabolic and cerebral blood flow alterations as well as emerging evidence on beta-amyloid, tau proteins and neuroinflammation.
conclusionsMolecular neuroimaging techniques, including Positron Emission Tomography (PET) and Single Photon Emission computed tomography (SPECT), provide valuable tools for tracking PD pathophysiology in vivo. Indeed, nuclear imaging is able to add information on genetic PD, offering possible biomarkers to stratify patients, predict cognitive decline, and support personalized therapeutic approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.